Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

This article was originally published in The Pink Sheet Daily

Executive Summary

Kalydeco, an oral CFTR potentiator, becomes the first approved drug to address the underlying cause of cystic fibrosis, rather than just treating the disease’s symptoms.

You may also be interested in...



Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way

Sales of key cystic fibrosis drugs will jump in western economies over the next decade, driven by strong uptake of high-cost CFTR modulator therapies and longer use as life expectancies improve, according to a new report by Datamonitor Healthcare.

Why Pricing Orkambi Below Kalydeco Is A Savvy Strategy For Vertex

Orkambi is the first combo drug to be priced lower than solo therapy with one of its components, but it stands to increase Vertex’s patient base exponentially.

Vertex’s Orkambi Approved With Broad Label For Cystic Fibrosis

Quick launch is planned, with firm having prepared ‘at risk of having a successful approval’ – patient screening and reimbursement shepherding are early areas of focus.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073330

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel